Showing 611 articles

  • NEW PharmiWeb Partners

    23 Oct 2020| Nola Cadman

    PharmiWeb Partners with major players in the Pharma Industry.

  • Teknova affirms commitment to customer-centric innovation with appointment of Neal Goodwin as Chief Scientific Officer

    14 Jan 2021| Nola Cadman

    Teknova—a leading manufacturer of cell culture media and supplements, purification buffers, and molecular biology reagents—welcomes Dr Neal Goodwin as Chief Scientific Officer (CSO).

  • ONK Therapeutics Appoints Hugh O’Dowd as Independent Chairman

    14 Jan 2021| Nola Cadman

    ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors.

  • Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

    14 Jan 2021| Nola Cadman

    Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

  • ZAGENO Announces New Leadership Appointments in Product and People Operations

    14 Jan 2021| Nola Cadman

    ZAGENO, a leading enterprise marketplace solution connecting eCommerce to life science, today announced the expansion of its US leadership team with the appointment of both Chief Product and Chief People Officers.

  • Rejuveron appoints anti-aging pioneer Aubrey de Grey to its Scientific Advisory Board

    14 Jan 2021| Nola Cadman

    Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy aging, today announced the appointment of biomedical gerontologist, Dr. Aubrey de Grey, to its Scientific Advisory Board (SAB).

  • Purespring appoints new Chief Executive Officer

    14 Jan 2021| Nola Cadman

    Purespring Therapeutics (Purespring), a kidney-focused AAV gene therapy company, announces that it is intended to appoint Richard Francis as Chief Executive Officer following the completion of its Series A financing of £45.0 million, from 1 February 2021.

  • AVECTAS Appoints Daniel Castro as Chief Business Officer

    12 Jan 2021| Mike Wood

    Avectas, a cell engineering company that has pioneered SOLUPORE®, a transformative non-viral cell engineering technology, to enable efficient and safe genetic modification of the next generation of cell therapies, announced today that Daniel Castro has been appointed as Chief Business Officer. In the newly created US-based role, Mr. Castro will lead Avectas' corporate strategy and business development, reporting to Michael Maguire PhD, Avectas’ CEO.

  • Major Life Science Companies Hiring in Australia Jan 2021

    7 Jan 2021| Mike Wood

    The Latest List (Jan 2021) of Life Science Companies Hiring in Australia and New Zealand.

  • PureTech Announces the Appointment of George Farmer, Ph.D., as Chief Financial Officer

    7 Jan 2021| Nola Cadman

    ) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., has been appointed Chief Financial Officer.


    7 Jan 2021| Nola Cadman

    Arrayjet, the Scottish-based bio-printing and microarray technology company, has announced the appointment of its new non-executive Chairman.

  • NuCana Appoints Andrew Kay as Board Chairman

    7 Jan 2021| Nola Cadman

    Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics

  • Sensyne Health appoints Tony Bourne to the Board as Independent Non-Executive Director

    7 Jan 2021| Nola Cadman

    Tony Bourne to join as Independent Non-Executive Director

  • Rinri Therapeutics (Private) Appoints Terri Gaskell, PhD as Chief Technology Officer

    7 Jan 2021| Nola Cadman

    Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing. The company’s pioneering technology seeks to reverse sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear. SNHL is estimated to affect 64 million patients in the US and 34 million in Europe. There are currently no pharmacological treatment options for SNHL patients.

  • The Dawn of a New Era for UK Clinical Research?

    6 Jan 2021| Nola Cadman

    On 28th January CCRA will host a webinar bringing together senior representatives of Government and regulators to discuss where we are now and the plans that are in place, or being formulated, to ensure that UK Clinical Research remains at the forefront of the global industry and remains an attractive proposition for pharma and biotech.

  • Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

    16 Dec 2020| Nola Cadman

    Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

  • Pill Connect expands its team with the appointment of Richard Hall as Director of Quality

    16 Dec 2020| Nola Cadman

    Pill Connect, which until recently was called Elucid mHealth, is a health technology company based in Manchester, UK

  • Investment to respond to growth in demand for integrated services at UK drug delivery company BDD

    16 Dec 2020| Nola Cadman

    BDD Pharma Ltd is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations, including its timed release platform technology, OralogiK™. BDD provides both development and clinical trial capabilities which enable rapid development and clinical testing of new pharmaceutical products.

  • PharmiWeb.Jobs Welcomes Albion Rye Associates

    16 Dec 2020| Nola Cadman

    About Albion Rye Associates in their own words..